New pill targets Cancer's 'Engine' in first human trial

NCT ID NCT07038369

First seen Nov 01, 2025 · Last updated Apr 10, 2026 · Updated 20 times

Summary

This is a first-in-human study to test the safety and find the right dose of an experimental pill called ATV-1601. It is for adults with advanced solid tumors, including certain breast, gynecologic, and prostate cancers, that have a specific genetic change called an AKT1 E17K mutation. The main goals are to see how the body processes the drug and what side effects it causes, while also looking for early signs that it might help control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre Leon Berard

    Lyon, 69008, France

  • Florida Cancer Specialists & Research Institute - Lake Mary

    Lake Mary, Florida, 32746, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • National Cancer Centre Singapore

    Singapore, 168583, Singapore

  • START Madrid - CIOCC

    Madrid, 28050, Spain

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • Washington University

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.